This open-label, Phase I trial (n=20) will study the safety and tolerability of psilocybin in individuals with chronic stroke. Participants will receive either a single 25 mg dose of psilocybin or a divided dose (12.5 mg followed by another 12.5 mg two hours later), to assess whether the compound is safe to use in this population. Secondary outcomes will explore psilocybin’s potential to aid motor recovery following stroke.
This Phase I, open-label trial (n=30) will study the psychological and biological effects of MDMA-assisted therapy in mental health providers who are training to become MDMA-assisted therapists. Participants will receive an initial oral dose of 120 mg of MDMA in a therapeutic setting, followed 1.5–2 hours later by a supplemental 40 mg dose, unless not tolerated or declined.
This double-blind, placebo-controlled, crossover trial (n=48) will study the effects of psilocybin (15 mg) on memory, cognition, and brain function in healthy adults. Participants will receive both psilocybin and placebo in separate sessions, in counterbalanced order, with testing involving computerised cognitive tasks and functional magnetic resonance imaging (fMRI) brain scans.
This Phase I, open-label, dose-escalation trial (n=10) will evaluate the safety and psychological effects of a combined psilocybin and D-Serine formulation; cohort 1 will receive psilocybin 15 mg with D-Serine 5 g, and if safe cohort 2 will receive psilocybin 25 mg with D-Serine 7 g.
This Phase II, assessor-blinded, randomised controlled trial (n=30) will study the effects of a single 25 mg oral dose of synthetic psilocybin, given with either standard psychological support or psychological support plus mindfulness-based cognitive therapy (MBCT), in adults with post-traumatic stress disorder (PTSD).
This Phase III, double-blind, randomised, placebo-controlled trial (n=30) will study the effects of intravenous ketamine (35mg/70kg) given during electroconvulsive therapy (ECT) sessions 2, 4, and 6 in adults with treatment-resistant major depressive disorder (MDD).
This randomised, double-blind, low-dose comparator-controlled Phase 2b trial (n=87) will study the effects of different doses of psilocybin (PEX010; 1-10-25mg)delivered during a psilocybin-assisted psychotherapy (PAP) session in individuals with adjustment disorder following a cancer diagnosis.
This retrospective, observational trial (n=250) will review patient charts to study the effects of intravenous racemic ketamine (a 50/50 mixture of S-ketamine and R-ketamine, given at sub-anaesthetic doses) for treatment-resistant depression in a real-world outpatient setting.
This open-label, Phase II trial (n=38) will assess the effects of intravenous ketamine (35mg/70kg, two infusions 24 hours apart) on symptoms of severe borderline personality disorder (BPD).
This open-label, randomised controlled Phase II trial (n=30) will test a six-week Fly-In-Fly-Out Psilocybin-Assisted Therapy (FIFO-PAT) programme for major depressive disorder (MDD), using a single 25 mg oral dose of psilocybin alongside psychotherapy and either a virtual-reality (VR) integration tool or journaling.
Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)
This Phase III, double-blind, placebo-controlled, parallel-arm trial (n=120) will study the effects of psilocybin microdosing (2–3mg, 4 days per week for 2 weeks) on psychological and existential distress in patients receiving palliative care for advanced illness.
This Phase II open-label trial (n=15) will study the effects of psilocybin (25mg) administered in the context of Psilocybin-assisted Existential, Attachment and Relational (PEARL) therapy for caregivers of patients with advanced cancer.
This Phase I randomised, single-blind trial (n=20) will study the effects of multiple low doses of psilocybin (MLS101) on brain activity, safety, tolerability, and pharmacokinetics in healthy adult volunteers.
This open-label, single-arm Phase IV trial (n=47) will evaluate the efficacy and safety of esketamine nasal spray (flexibly dosed at 56mg or 84mg) in Korean adults with treatment-resistant depression (TRD).
This early Phase I, randomised, placebo-controlled trial (n=48) will study the psychological and behavioural effects of a low dose of LSD (13µg) by comparing participants' experiences when they do or do not know what drug they are receiving.
This open-label Phase I/II trial (n=12) will study the effects of oral ketamine (beginning at 35mg/70kg and increasing to 140mg/70kg) in combination with prolonged exposure therapy for the treatment of post-traumatic stress disorder (PTSD).
This randomised, double-blind, placebo-controlled Phase IV trial (n=50) will study the effects of a single low-dose intravenous infusion of esketamine (14mg/70kg over 40 minutes) combined with oral duloxetine (60mg/day) on depression in patients with postherpetic neuralgia (nerve pain that continues after a shingles infection).
This open-label, randomised controlled trial (n=30) will study whether ketamine (four infusions over two weeks) combined with mindfulness-based cognitive therapy improves quality of life, pain, depression, and PTSD symptoms more effectively than mindfulness therapy alone in adults with both chronic pain and PTSD.
This observational trial (n=100) will study the metabolic effects of esketamine (administered nasally) in patients with treatment-resistant major depressive disorder (TRD), using a non-targeted metabolomic approach to identify changes in biochemical pathways.
This Phase II, randomised, placebo-controlled, double-blind trial (n=75) will assess the therapeutic effects of a single intravenous dose of ketamine (56mg/70kg) combined with real-time fMRI neurofeedback (rt-fMRI NFT) on alcohol use disorder (AUD).
This randomised, double-blind, placebo-controlled Phase II trial (n=60) will study the feasibility, safety, and acceptability of oral ketamine (60–180 mg, administered twice weekly) as a treatment for adults with long-standing anorexia nervosa and comorbid treatment-resistant depression.
This Phase IIa, placebo-controlled, double-blind trial (n=50) will study the safety, tolerability, and preliminary efficacy of a 3 mg dose of psilocybin (oral solution) in adults with generalised anxiety disorder (GAD).
This open-label, randomised crossover trial (n=25) will investigate the effects of intravenous (IV) ketamine (35mg/70kg over one hour) combined with different music conditions—self-selected music, therapist-selected music, or silence—on chronic noncancer pain.
This open-label Phase I trial (n=15) will assess the feasibility and safety of a single 25 mg dose of pharmaceutical-grade psilocybin combined with psychotherapy in women aged 18–45 with chronic pelvic pain (CPP) who have not responded to at least one conventional treatment.
This randomised, double-masked Phase I/II trial (n=20) will study the safety, tolerability, and efficacy of psilocybin (10mg vs 30mg) across four sessions for the treatment of obsessive-compulsive disorder (OCD).
This Phase I, double-blind, active-controlled trial (n=40) will investigate the safety and potential therapeutic effects of co-administered MDMA and psilocybin in military Veterans diagnosed with post-traumatic stress disorder (PTSD).
This Phase I, open-label trial (n=4) will assess the safety and pharmacokinetics of a single intravenous dose of psilocin (TRP-8803; 5 mg loading over 20 minutes followed by 5 mg maintenance over 120 minutes) in healthy adults undergoing psychedelic-assisted psychotherapy.
This randomised, double-blind, placebo-controlled Phase III trial (n=140) will evaluate the efficacy and safety of a single oral dose of MM120 (100 µg LSD D-tartrate) for the treatment of major depressive disorder (MDD).
This randomised, double-blind, placebo-controlled Phase III trial (n=60) will investigate the efficacy and safety of subcutaneous ketamine (35-70mg/70kg, twice weekly for four weeks) as an add-on treatment for adolescents experiencing a major depressive episode with suicidal ideation and/or behaviour.
This randomised, quadruple-blind, placebo-controlled Phase II trial (n=50) will assess the effects of ketamine (52.5mg/70kg, intramuscularly, four times over two weeks) on opioid craving and withdrawal symptoms in adults newly entering methadone treatment for opioid use disorder.
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
